TransMedics Group (TransMedics Group) Total Inventories

: $44.2 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

TransMedics Group's total inventories for the quarter that ended in Dec. 2023 was $44.2 Mil. TransMedics Group's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $41.8 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. TransMedics Group's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-3.19.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. TransMedics Group's Days Inventory for the three months ended in Dec. 2023 was 114.71.

Inventory Turnover measures how fast the company turns over its inventory within a year. TransMedics Group's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.80.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. TransMedics Group's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.51.

TransMedics Group Total Inventories Historical Data

The historical data trend for TransMedics Group's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Array ( [0] => - [1] => - [2] => - [3] => 11.22 [4] => 11.93 [5] => 14.86 [6] => 20.61 [7] => 44.24 )

TransMedics Group Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

11.22

11.93

14.86

20.61

44.24

TransMedics Group Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Inventories																20.61	23.96	30.55	39.37	44.24

TransMedics Group Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

TransMedics Group (NAS:TMDX) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

TransMedics Group's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(394.812	+	0.75 * 63.576	+	0.5 * 44.235	-	568.845
-	0	-	0)	/	32.6708
=	-3.19

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

TransMedics Group's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	41.8	/	33.25	*	365 / 4
	=	114.71

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

TransMedics Group's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	33.25	/	41.8
	=	0.80

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

TransMedics Group's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	41.8	/	81.174
	=	0.51

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

TransMedics Group Total Inventories Related Terms

Thank you for viewing the detailed overview of TransMedics Group's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

TransMedics Group (TransMedics Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TransMedics Group Inc (NAS:TMDX) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

8T8:Germany TMDX:Germany

Address

200 Minuteman Road, Andover, MA, USA, 01810

Website

https://www.transmedics.com

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body.

Executives

Tamer I Khayal	officer: Chief Commercial Officer	TRANSMEDICS INC, 200 MINUTEMAN ROAD, ANDOVER MA 01810
Miriam Provost	officer: VP of US Regulatory & FDA Rel.	2000 MINUTEMAN ROAD, ANDOVER MA 01810
Waleed H Hassanein	director, officer: President & CEO	TRANSMEDICS INC, 200 MINUTEMAN ROAD, ANDOVER MA 01810
James R Tobin	director	C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Stephen Gordon	officer: Chief Financial Officer	200 MINUTEMAN ROAD, ANDOVER MA 01810
David Weill	director	200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Anil P. Ranganath	officer: See Remarks	C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Edward M Basile	director	200 MINUTEMAN ROAD, ANDOVER MA 01810
John F Carey	officer: VP of Operations	200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Nicholas Corcoran	officer: See Remarks	C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Laura Damme	officer: VP, Clinical Affairs	C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Stephanie Lovell	director	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Kania Edwin M Jr	director
Rakesh P. Godhani	officer: Chief Digital Officer	C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
John F Sullivan	officer: VP of Quality & Engineering	200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810